Skip to content
Medical Health Aged Care

Memory Walk & Jog is heading to Western Sydney!

Dementia Australia 2 mins read

What started as one event has grown to a movement across Australia, and in six weeks Memory Walk & Jog will take place in Western Sydney.

 

Dementia Australia’s largest fundraising event is heading back to Western Sydney after a great event last year with walkers, runners and joggers setting off on Sunday 10 March at Tench Reserve. Last year, more than 10,000 people walked, jogged and ran in cities and towns across Australia for people impacted by dementia. This year we’re hoping to go even bigger and want more people to sign-up and assist us in raising more than $2 million which will help fund invaluable support, education and resources for people living with dementia in Australia, their families and carers.

 

There are more than 421,000 people of all ages living with dementia in Australia. Without a medical breakthrough, the number of people living with dementia is expected to increase to more than 812,500 by 2054. Dementia is the second leading cause of death in Australia and the leading cause of death for women. Memory Walk & Jog plays an important role not only in funding support, but also in raising awareness of dementia.    

 

 Walk or jog with us. We are in this together. 

 

Sign-up to walk, jog or run, or join in as a volunteer, at a Memory Walk & Jog event at www.memorywalk.com.au. Share your Memory Walk & Jog experience on your socials and Donate today to support people living with dementia across Australia. 

 

If you can’t attend an event, why not organise your own group or individual walk or jog, with a My Way event. Choose your own date and location and register at www.memorywalk.com.au/get-involved/mw.

 

 

Dementia Australia is the source of trusted information, education and services for the estimated more than 421,000 Australians living with dementia, and the more than 1.6 million people involved in their care. We advocate for positive change and support vital research. We are here to support people impacted by dementia, and to enable them to live as well as possible. No matter how you are impacted by dementia or who you are, we are here for you.  

 

For support, please contact the National Dementia Helpline on 1800 100 500. An interpreter service is available. The National Dementia Helpline is funded by the Australian Government. People looking for information can also visit dementia.org.au   

 

-Ends-

Media contacts: Ash Blakemore, Senior Media & Communications Advisor, 0448 170 672, ash.blakemore@dementia.org.au. Andrea Hogan, Media and Communications Manager, 0406 904 118, andrea.hogan@dementia.org.au

When talking or writing about dementia please refer to Dementia-Friendly Language Guidelines.

Note to Editors: We request, where possible, details for the National Dementia Helpline 1800 100 500 appear alongside news stories about dementia, as these stories often prompt questions or concerns:

If this story has prompted any questions or concerns, please call the National Dementia Helpline 1800 100 500 (24 hours, 7 days a week) or visit dementia.org.au.

Media

More from this category

  • Medical Health Aged Care
  • 31/10/2024
  • 17:55
Kyowa Kirin Co., Ltd.

Kyowa Kirin Announces Changes in Top Leadership Positions to Strengthen Operations as a Global Specialty Pharmaceutical Company

Masashi Miyamoto to be named Chairman and CEO Abdul Mullick to be named President and COO Changes designed to further deliver on company’s 2030…

  • Contains:
  • Medical Health Aged Care
  • 31/10/2024
  • 12:10
MannKind

First Site Initiated in Australia for MannKind’s Phase 3 Clinical Trial Evaluating Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial (NTM) Lung Disease

ICoN-1 study presentation planned November 1 at NTM Symposium AustraliaStudy is cleared by health authorities to proceed in Australia, U.S., Japan and South Korea, with Taiwan anticipated by end of year DANBURY, Conn., Oct. 30, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of innovative inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, announced today that it has initiated its first site for its Phase 3 clinical trial evaluating efficacy and safety of Clofazimine Inhalation Suspension for the treatment of nontuberculous mycobacterial (NTM) lung disease. The study,…

  • Business Company News, Medical Health Aged Care
  • 31/10/2024
  • 11:03
Firebrick Pharma

Agreement Signed to Market Nasodine to Healthcare Professionals in Singapore

Firebrick Pharmais pleased to announce that it has executed a Marketing Representation Agreement (the “Agreement”) with Singapore-based, Innorini, trading as Innorini Life Sciences (“Innorini”). The initial term of the Agreement is one year with the option to renew for subsequent one-year terms by mutual agreement. Under the Agreement, Innorini will undertake “Marketing Services” commencing 1 November 2024. The Marketing Services comprise sampling and promotion of Nasodine® Nasal Spray (“Nasodine”) to General Practitioners (“GPs”) and hospital-based doctors and pharmacists (collectively “HCPs”) in Singapore. In addition to building awareness and support of Nasodine by HCPs, Innorini will be expected to sell Nasodine…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.